Bergstra A, Simsek C, van den Heuvel A F M
Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Department of Cardiology, Amphia Ziekenhuis, Breda, The Netherlands.
Neth Heart J. 2020 May;28(5):266-271. doi: 10.1007/s12471-020-01417-x.
Although mitral regurgitation (MR) is the most common valvular heart disease, it should be regarded as a complex multifactorial disease that involves multiple entities. Optimal medical therapy alone does not hinder the progression of the disease, and in the 1980s it was already recognised that corrective surgery is indicated if MR is severe and patients are symptomatic (except for those with the most severe left ventricle dysfunction). Later on, asymptomatic patients with deterioration of the left ventricular ejection fraction were also operated on to avoid irreversible left ventricular dysfunction, heart failure and eventually death. However, a major drawback remains the fact that a significant group of patients is considered to have a high perioperative risk due to their advanced age or severe comorbidities. Since less invasive, percutaneous interventions have been developed and recently thoroughly investigated in the MITRA-FR and the COAPT studies, the type of intervention and also the timing have become more crucial. In this critical review of the literature, we describe what we should have learned from the past and which (haemodynamic) parameters can best predict the outcome in patients with MR.
尽管二尖瓣反流(MR)是最常见的心脏瓣膜病,但它应被视为一种涉及多个实体的复杂多因素疾病。仅靠最佳药物治疗并不能阻止疾病的进展,早在20世纪80年代就已认识到,如果MR严重且患者有症状(最严重左心室功能障碍患者除外),则应进行矫正手术。后来,左心室射血分数恶化的无症状患者也接受了手术,以避免不可逆的左心室功能障碍、心力衰竭并最终死亡。然而,一个主要缺点仍然是,相当一部分患者由于年龄较大或合并症严重,被认为围手术期风险很高。由于已开发出侵入性较小的经皮干预措施,并且最近在MITRA-FR和COAPT研究中进行了全面研究,干预类型以及时机变得更加关键。在对文献的这一批判性综述中,我们描述了我们应该从过去学到的东西,以及哪些(血流动力学)参数能够最好地预测MR患者的预后。